Mitochondria-targeting damage has become a popular therapeutic
option for tumor metastasis; however, its efficacy is limited by the
adaptive rescue capacity of nuclei. There is an urgent need for a
dual mitochondrial and nuclear targeting strategy that can also increase
the antitumor capacity of macrophages. In this study, XPO1 inhibitor
KPT-330 nanoparticles were combined with mitochondria-targeting lonidamine
(TPP-LND) nanoparticles. The combination of nanoparticles with a 1:4
ratio of KPT and TL demonstrated the best synergistic effect in restraining
the proliferation and metastasis of 4T1 breast cancer cells. Investigating
the mechanisms both in vitro and in vivo, it was found that KPT nanoparticles not only directly impede tumor
growth and metastasis by controlling the expression of associated
proteins but also indirectly facilitate mitochondrial damage. The
two nanoparticles synergistically decreased the expression of cytoprotective
factors, such as Mcl-1 and Survivin, causing mitochondrial dysfunction
and thus inducing apoptosis. Additionally, it downregulated metastasis-related
proteins like HIF-1α, vascular endothelial growth factor (VEGF),
and matrix metalloproteinase 2 (MMP-2) and reduced endothelial-to-mesenchymal
transition. Significantly, their combination increased the ratio of
M1 tumor-associated macrophages (TAMs)/M2 TAMs both in vitro and in vivo and increased the phagocytosis of tumor
cells by macrophages, thus suppressing tumor growth and metastasis.
In summary, this research revealed that nuclear export inhibition
can synergistically enhance the prevention of mitochondrial damage
to tumor cells, heightening the antitumor properties of TAMs, thereby
providing a viable and safe therapeutic approach for the treatment
of tumor metastasis.